AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
fosdenopterin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| insecticides, anthelminthics, pesticides etc., phosphorous derivatives | 5444 | 150829-29-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Fosdenopterin provides an exogenous source of cPMP. cPMP is converted to molybdopterin, which is then converted to molybdenum cofactor (MoCo) and restores molybdenum cofactor biosynthesis. In MOCD Type A, mutations in MOCS1 lead to deficient MOCS1A/B-dependent synthesis of cPMP, which subsequently results in deficient molybdenum-dependent enzyme activity (e.g., sulfite oxidase).
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 63 | mg | P |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,NTRK1,NTRK2,PDK1,PDK2,PIK3CB,PIK3CD,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1 | 42 | |||
| kinase-selectivity-class | AXL,CDK9,GRK2,MAP2K6,MAP3K14,MAPK7,PIK3CD,TEK | 8 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 26, 2021 | FDA | ORIGIN | |
| Sept. 15, 2022 | EMA | COMHARSA LIFE SCIENCES LTD |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A16AX19 | ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Various alimentary tract and metabolism products |
| FDA EPC | N0000193919 | Cyclic Pyranopterin Monophosphate |
| FDA EXT | N0000193920 | Cyclic Pyranopterin Monophosphate |
Related Drugs by ATC class:
A16AX Various alimentary tract and metabolism products 23 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Molybdenum cofactor deficiency type A | indication | 29692004 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 9.5MG BASE/VIAL | NULIBRY | SENTYNL THERAPS INC | N214018 | Feb. 26, 2021 | RX | POWDER | INTRAVENOUS | 7504095 | April 9, 2029 | METHOD OF TREATING MOLYBDENUM COFACTOR DEFICIENCY TYPE A |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 9.5MG BASE/VIAL | NULIBRY | SENTYNL THERAPS INC | N214018 | Feb. 26, 2021 | RX | POWDER | INTRAVENOUS | Feb. 26, 2026 | NEW CHEMICAL ENTITY |
| EQ 9.5MG BASE/VIAL | NULIBRY | SENTYNL THERAPS INC | N214018 | Feb. 26, 2021 | RX | POWDER | INTRAVENOUS | Feb. 26, 2028 | INDICATED TO REDUCE THE RISK OF MORTALITY IN PATIENTS WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Molybdenum cofactor biosynthesis protein 1 | Enzyme | UNKNOWN | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| D11779 | KEGG_DRUG |
| 4X7K2681Y7 | UNII |
| 2301083-34-9 | SECONDARY_CAS_RN |
| C2934004 | UMLSCUI |
| CHEMBL2338675 | ChEMBL_ID |
| 135463437 | PUBCHEM_CID |
| DB16628 | DRUGBANK_ID |
| CHEMBL4594300 | ChEMBL_ID |
| 11150 | INN_ID |
| C549445 | MESH_SUPPLEMENTAL_RECORD_UI |
| 1149378000 | SNOMEDCT_US |
| 1153617008 | SNOMEDCT_US |
| 1179070005 | SNOMEDCT_US |
| 4040183 | VANDF |
| CHEBI:757802 | CHEBI |
| 343975 | MMSL |
| 39338 | MMSL |
| d09717 | MMSL |
| 018652 | NDDF |
| 018656 | NDDF |
| 2531287 | RXNORM |
| 4X7K2681Y7 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Nulibry | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42358-295 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 9.50 mg | INTRAVENOUS | NDA | 28 sections |